---
schema_version: "secwatch.filing_event.v1"
accession: "0001157523-23-000343"
form_type: "8-K"
ticker: "EWTX"
cik: "0001710072"
company_name: "Edgewise Therapeutics, Inc."
filed_at: "2023-02-23T23:59:59+00:00"
generated_at: "2026-06-19T02:59:06.314559+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Edgewise reports Q4 2022 net loss $19.4M; cash $352M; advancing EDG-5506 and EDG-7500 trials

## Summary
- Cash, cash equivalents and marketable securities of $352M as of Dec 31, 2022.
- Q4 2022 net loss $19.4M ($0.31 per share); R&D expenses $16.6M, G&A $5.5M.
- EDG-7500 for HCM entered IND-enabling studies; Phase 1 start expected 2H2023.
- LYNX Phase 2 DMD trial interim data expected Q4 2023; ARCH BMD 12-month data Q2 2023.
- CANYON BMD trial to be amended with potentially registration-enabling cohort in 2H2023.

## SEC filing metadata
- accession: 0001157523-23-000343
- form_type: 8-K
- ticker: EWTX
- cik: 0001710072
- company_name: Edgewise Therapeutics, Inc.
- filed_at: 2023-02-23T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1710072/000115752323000343/0001157523-23-000343-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1710072/000115752323000343/a53339740.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001157523-23-000343
- JSON: https://secwatch.observer/filing/0001157523-23-000343.json
- Plain text: https://secwatch.observer/filing/0001157523-23-000343.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.